Version 1
: Received: 6 November 2023 / Approved: 6 November 2023 / Online: 7 November 2023 (02:49:35 CET)
How to cite:
Petrović, M.; Brković, V.; Baralić, M.; Maric, I.; Petković, N.; Stankovic, S.; Lalic, N.; Stanisavljevic, D.; Ležaić, V. Comparative Analysis of Vascular Calcification Risk Factors and Biomarkers in Pre-Hemodialysis and Prevalent Hemodialysis Patients. Preprints2023, 2023110339. https://doi.org/10.20944/preprints202311.0339.v1
Petrović, M.; Brković, V.; Baralić, M.; Maric, I.; Petković, N.; Stankovic, S.; Lalic, N.; Stanisavljevic, D.; Ležaić, V. Comparative Analysis of Vascular Calcification Risk Factors and Biomarkers in Pre-Hemodialysis and Prevalent Hemodialysis Patients. Preprints 2023, 2023110339. https://doi.org/10.20944/preprints202311.0339.v1
Petrović, M.; Brković, V.; Baralić, M.; Maric, I.; Petković, N.; Stankovic, S.; Lalic, N.; Stanisavljevic, D.; Ležaić, V. Comparative Analysis of Vascular Calcification Risk Factors and Biomarkers in Pre-Hemodialysis and Prevalent Hemodialysis Patients. Preprints2023, 2023110339. https://doi.org/10.20944/preprints202311.0339.v1
APA Style
Petrović, M., Brković, V., Baralić, M., Maric, I., Petković, N., Stankovic, S., Lalic, N., Stanisavljevic, D., & Ležaić, V. (2023). Comparative Analysis of Vascular Calcification Risk Factors and Biomarkers in Pre-Hemodialysis and Prevalent Hemodialysis Patients. Preprints. https://doi.org/10.20944/preprints202311.0339.v1
Chicago/Turabian Style
Petrović, M., Dejana Stanisavljevic and Višnja Ležaić. 2023 "Comparative Analysis of Vascular Calcification Risk Factors and Biomarkers in Pre-Hemodialysis and Prevalent Hemodialysis Patients" Preprints. https://doi.org/10.20944/preprints202311.0339.v1
Abstract
Introduction. This retrospective study aimed to compare the risk factors for vascular calcification (VC) between pre-hemodialysis (HD) and prevalent HD adult patients while investigating associations with calcification biomarkers.
Methods. Baseline data from 30 pre-HD and 85 HD patients were analyzed, including iPTH, vitamin D, FGF23, fetuinA, sclerostin, and VC scores (Adragao method). Multivariable linear regression identified VC predictors.
Results: The prevalence of VC was similar in both groups, but HD patients had more pronounced VC scores ≥6. Pre-HD patients were older, with higher prevalence of Balkan endemic nephropathy, hypertension, and less frequent use of calcium phosphate binders. Both groups exhibited similar patterns of hyperphosphatemia, low vitamin D, and iPTH levels. In HD group normal phosphate was significantly common in patients with VC, whereas hyperphosphatemia was significantly common in patients without VC. Fetuin-A levels were higher in pre-HD patients, while FGF23 was elevated in HD patients. In pre-HD patients, male gender was associated with reduced VC risk, while in HD patients, malignancies and serum phosphate levels were negative VC predictors.
Conclusion: Effective monitoring and tailored treatment of VC in CKD are still focused on phosphate regulation. Besides, mineral disturbances, hormones and biomarkers regulation, and patient-specific variables need to be considered.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.